Cargando…

FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis

BACKGROUND: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. It is characterized by inflammation and leukocyte infiltration that can progress to intestinal necrosis, perforation, systemic inflammatory response, and death. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckert, Jeffrey, Scott, Brian, Lawrence, Shelley M, Ihnat, Michael, Chaaban, Hala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476581/
https://www.ncbi.nlm.nih.gov/pubmed/28652797
http://dx.doi.org/10.2147/JIR.S131051
_version_ 1783244614655803392
author Eckert, Jeffrey
Scott, Brian
Lawrence, Shelley M
Ihnat, Michael
Chaaban, Hala
author_facet Eckert, Jeffrey
Scott, Brian
Lawrence, Shelley M
Ihnat, Michael
Chaaban, Hala
author_sort Eckert, Jeffrey
collection PubMed
description BACKGROUND: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. It is characterized by inflammation and leukocyte infiltration that can progress to intestinal necrosis, perforation, systemic inflammatory response, and death. In this study, we examined the effect of FLLL32, a curcumin analog, on an NEC-like neonatal intestinal injury model. METHODS: NEC was induced in CD-1 mice pups using the Paneth cell ablation and Klebsiella infection model. Pups were divided into sham, NEC, and NEC + FLLL32 groups. At the end of the experiment, pups were euthanized; whole blood and small intestines were harvested. Intestinal inflammatory cytokine profile, in vivo intestinal permeability using serum fluorescein isothiocyanate-dextran, and histological injury scores were compared between the groups. RESULTS AND CONCLUSION: FLLL32-treated pups had lower intestinal injury, improved intestinal permeability, and lower proinflammatory cytokine profiles compared to those in untreated pups with NEC. These results suggest that FLLL32 plays a protective role in NEC.
format Online
Article
Text
id pubmed-5476581
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54765812017-06-26 FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis Eckert, Jeffrey Scott, Brian Lawrence, Shelley M Ihnat, Michael Chaaban, Hala J Inflamm Res Original Research BACKGROUND: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. It is characterized by inflammation and leukocyte infiltration that can progress to intestinal necrosis, perforation, systemic inflammatory response, and death. In this study, we examined the effect of FLLL32, a curcumin analog, on an NEC-like neonatal intestinal injury model. METHODS: NEC was induced in CD-1 mice pups using the Paneth cell ablation and Klebsiella infection model. Pups were divided into sham, NEC, and NEC + FLLL32 groups. At the end of the experiment, pups were euthanized; whole blood and small intestines were harvested. Intestinal inflammatory cytokine profile, in vivo intestinal permeability using serum fluorescein isothiocyanate-dextran, and histological injury scores were compared between the groups. RESULTS AND CONCLUSION: FLLL32-treated pups had lower intestinal injury, improved intestinal permeability, and lower proinflammatory cytokine profiles compared to those in untreated pups with NEC. These results suggest that FLLL32 plays a protective role in NEC. Dove Medical Press 2017-06-14 /pmc/articles/PMC5476581/ /pubmed/28652797 http://dx.doi.org/10.2147/JIR.S131051 Text en © 2017 Eckert et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Eckert, Jeffrey
Scott, Brian
Lawrence, Shelley M
Ihnat, Michael
Chaaban, Hala
FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis
title FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis
title_full FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis
title_fullStr FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis
title_full_unstemmed FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis
title_short FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis
title_sort flll32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476581/
https://www.ncbi.nlm.nih.gov/pubmed/28652797
http://dx.doi.org/10.2147/JIR.S131051
work_keys_str_mv AT eckertjeffrey flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis
AT scottbrian flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis
AT lawrenceshelleym flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis
AT ihnatmichael flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis
AT chaabanhala flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis